QuantRx Biomedical Corporation (QTXB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -476.7 Thousand USD | -1.54% |
| 2020 | -469.45 Thousand USD | 42.76% |
| 2019 | -820.1 Thousand USD | -11.3% |
| 2018 | -736.85 Thousand USD | -184.78% |
| 2017 | 869.13 Thousand USD | 318.38% |
| 2016 | -397.99 Thousand USD | 14.92% |
| 2015 | -467.78 Thousand USD | 43.44% |
| 2014 | -826.98 Thousand USD | -130.79% |
| 2013 | -358.33 Thousand USD | 50.09% |
| 2012 | -717.96 Thousand USD | 8.38% |
| 2011 | -783.61 Thousand USD | -194.28% |
| 2010 | 831.18 Thousand USD | 126.36% |
| 2009 | -3.15 Million USD | 59.16% |
| 2008 | -7.72 Million USD | -27.75% |
| 2007 | -6.04 Million USD | 21.43% |
| 2006 | -7.69 Million USD | -604.08% |
| 2005 | -1.09 Million USD | -5406.29% |
| 2004 | -19.84 Thousand USD | 57.24% |
| 2003 | -46.4 Thousand USD | 62.59% |
| 2002 | -124.03 Thousand USD | 85.74% |
| 2001 | -870 Thousand USD | 52.2% |
| 2000 | -1.82 Million USD | 26.91% |
| 1999 | -2.49 Million USD | 46.22% |
| 1998 | -4.63 Million USD | -132.66% |
| 1997 | -1.99 Million USD | 54.04% |
| 1996 | -4.33 Million USD | -3.1% |
| 1995 | -4.2 Million USD | -300.0% |
| 1994 | -1.05 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | 100.0% |
| 2022 Q1 | -57.48 Thousand USD | 5.82% |
| 2022 Q2 | -80.81 Thousand USD | -40.58% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q3 | -61.16 Thousand USD | 24.31% |
| 2021 Q3 | -63.01 Thousand USD | 18.15% |
| 2021 Q2 | -76.99 Thousand USD | -30.5% |
| 2021 FY | -476.7 Thousand USD | -1.54% |
| 2021 Q1 | -58.99 Thousand USD | 7.18% |
| 2021 Q4 | -61.03 Thousand USD | 3.14% |
| 2020 Q3 | -65.16 Thousand USD | 17.86% |
| 2020 Q4 | -63.56 Thousand USD | 2.46% |
| 2020 Q2 | -79.33 Thousand USD | -77.59% |
| 2020 Q1 | -44.67 Thousand USD | 85.7% |
| 2020 FY | -469.45 Thousand USD | 42.76% |
| 2019 FY | -820.1 Thousand USD | -11.3% |
| 2019 Q1 | -112.21 Thousand USD | 78.12% |
| 2019 Q2 | -97.47 Thousand USD | 13.14% |
| 2019 Q3 | -99.73 Thousand USD | -2.32% |
| 2019 Q4 | -312.49 Thousand USD | -213.33% |
| 2018 Q3 | 23.78 Thousand USD | 116.67% |
| 2018 Q4 | -512.96 Thousand USD | -2256.69% |
| 2018 Q2 | -142.66 Thousand USD | -35.87% |
| 2018 Q1 | -105 Thousand USD | -109.38% |
| 2018 FY | -736.85 Thousand USD | -184.78% |
| 2017 Q3 | -33.31 Thousand USD | 63.61% |
| 2017 FY | 869.13 Thousand USD | 318.38% |
| 2017 Q1 | -92.67 Thousand USD | 7.6% |
| 2017 Q2 | -91.56 Thousand USD | 1.2% |
| 2017 Q4 | 1.11 Million USD | 3460.71% |
| 2016 FY | -397.99 Thousand USD | 14.92% |
| 2016 Q1 | -73.22 Thousand USD | 19.31% |
| 2016 Q4 | -100.29 Thousand USD | 13.65% |
| 2016 Q3 | -116.14 Thousand USD | -7.2% |
| 2016 Q2 | -108.33 Thousand USD | -47.96% |
| 2015 Q2 | -54.24 Thousand USD | 74.53% |
| 2015 FY | -467.78 Thousand USD | 43.44% |
| 2015 Q4 | -90.74 Thousand USD | 17.38% |
| 2015 Q1 | -212.97 Thousand USD | 5.24% |
| 2015 Q3 | -109.82 Thousand USD | -102.46% |
| 2014 Q3 | -157.74 Thousand USD | 39.35% |
| 2014 Q4 | -224.75 Thousand USD | -42.48% |
| 2014 Q1 | -184.37 Thousand USD | -17.52% |
| 2014 Q2 | -260.11 Thousand USD | -41.08% |
| 2014 FY | -826.98 Thousand USD | -130.79% |
| 2013 Q2 | -98.77 Thousand USD | -141.42% |
| 2013 Q3 | -61.74 Thousand USD | 37.49% |
| 2013 Q4 | -156.89 Thousand USD | -154.09% |
| 2013 Q1 | -40.91 Thousand USD | 72.33% |
| 2013 FY | -358.33 Thousand USD | 50.09% |
| 2012 Q4 | -147.89 Thousand USD | 9.17% |
| 2012 Q2 | -218.14 Thousand USD | -15.35% |
| 2012 Q3 | -162.81 Thousand USD | 25.36% |
| 2012 Q1 | -189.11 Thousand USD | 33.99% |
| 2012 FY | -717.96 Thousand USD | 8.38% |
| 2011 Q4 | -286.48 Thousand USD | -105.68% |
| 2011 FY | -783.61 Thousand USD | -194.28% |
| 2011 Q3 | -139.28 Thousand USD | -510.32% |
| 2011 Q2 | -22.82 Thousand USD | 93.19% |
| 2011 Q1 | -335.02 Thousand USD | -121.53% |
| 2010 FY | 831.18 Thousand USD | 126.36% |
| 2010 Q3 | -561.03 Thousand USD | -445.99% |
| 2010 Q1 | -326.24 Thousand USD | 67.64% |
| 2010 Q2 | 162.15 Thousand USD | 149.7% |
| 2010 Q4 | 1.55 Million USD | 377.4% |
| 2009 Q3 | -254.3 Thousand USD | 66.13% |
| 2009 Q2 | -750.9 Thousand USD | 41.51% |
| 2009 Q4 | -1 Million USD | -296.43% |
| 2009 Q1 | -1.28 Million USD | 14.14% |
| 2009 FY | -3.15 Million USD | 59.16% |
| 2008 Q2 | -2.14 Million USD | -6.16% |
| 2008 Q1 | -2.01 Million USD | -61.75% |
| 2008 FY | -7.72 Million USD | -27.75% |
| 2008 Q4 | -1.49 Million USD | 27.67% |
| 2008 Q3 | -2.06 Million USD | 3.46% |
| 2007 Q3 | -1.32 Million USD | 45.27% |
| 2007 FY | -6.04 Million USD | 21.43% |
| 2007 Q2 | -2.42 Million USD | -132.12% |
| 2007 Q4 | -1.24 Million USD | 6.04% |
| 2007 Q1 | -1.04 Million USD | 51.05% |
| 2006 Q4 | -2.13 Million USD | -8.86% |
| 2006 Q2 | -2.03 Million USD | -29.9% |
| 2006 Q1 | -1.56 Million USD | -398.22% |
| 2006 FY | -7.69 Million USD | -604.08% |
| 2006 Q3 | -1.96 Million USD | 3.54% |
| 2005 Q3 | -518.06 Thousand USD | -141.74% |
| 2005 Q1 | -46.1 Thousand USD | -1368.04% |
| 2005 Q4 | -314.07 Thousand USD | 39.38% |
| 2005 FY | -1.09 Million USD | -5406.29% |
| 2005 Q2 | -214.3 Thousand USD | -364.81% |
| 2004 Q1 | -11.47 Thousand USD | 0.0% |
| 2004 Q2 | -3024.00 USD | 73.65% |
| 2004 Q3 | -6566.00 USD | -117.13% |
| 2004 Q4 | 3636.00 USD | 155.38% |
| 2004 FY | -19.84 Thousand USD | 57.24% |
| 2003 FY | -46.4 Thousand USD | 62.59% |
| 2002 FY | -124.03 Thousand USD | 85.74% |
| 2002 Q1 | -40 Thousand USD | 60.0% |
| 2001 Q4 | -100 Thousand USD | 47.37% |
| 2001 FY | -870 Thousand USD | 52.2% |
| 2001 Q3 | -190 Thousand USD | 29.63% |
| 2001 Q2 | -270 Thousand USD | 12.9% |
| 2001 Q1 | -310 Thousand USD | 32.61% |
| 2000 Q4 | -460 Thousand USD | 6.12% |
| 2000 FY | -1.82 Million USD | 26.91% |
| 2000 Q1 | -430 Thousand USD | 17.31% |
| 2000 Q2 | -440 Thousand USD | -2.33% |
| 2000 Q3 | -490 Thousand USD | -11.36% |
| 1999 Q4 | -520 Thousand USD | 16.13% |
| 1999 Q3 | -620 Thousand USD | 4.62% |
| 1999 Q1 | -700 Thousand USD | 45.74% |
| 1999 FY | -2.49 Million USD | 46.22% |
| 1999 Q2 | -650 Thousand USD | 7.14% |
| 1998 Q2 | -910 Thousand USD | 24.79% |
| 1998 Q1 | -1.21 Million USD | 27.11% |
| 1998 Q3 | -1.22 Million USD | -34.07% |
| 1998 Q4 | -1.29 Million USD | -5.74% |
| 1998 FY | -4.63 Million USD | -132.66% |
| 1997 Q4 | -1.66 Million USD | -121.33% |
| 1997 FY | -1.99 Million USD | 54.04% |
| 1997 Q3 | -750 Thousand USD | -171.43% |
| 1997 Q2 | 1.05 Million USD | 264.06% |
| 1997 Q1 | -640 Thousand USD | 58.17% |
| 1996 Q2 | -1.07 Million USD | -5.94% |
| 1996 FY | -4.33 Million USD | -3.1% |
| 1996 Q4 | -1.53 Million USD | -112.5% |
| 1996 Q3 | -720 Thousand USD | 32.71% |
| 1996 Q1 | -1.01 Million USD | 9.01% |
| 1995 Q3 | -1 Million USD | 13.04% |
| 1995 Q4 | -1.11 Million USD | -11.0% |
| 1995 Q2 | -1.15 Million USD | -22.34% |
| 1995 Q1 | -940 Thousand USD | -80.77% |
| 1995 FY | -4.2 Million USD | -300.0% |
| 1994 Q1 | -230 Thousand USD | 0.0% |
| 1994 Q3 | -140 Thousand USD | 12.5% |
| 1994 Q4 | -520 Thousand USD | -271.43% |
| 1994 Q2 | -160 Thousand USD | 30.43% |
| 1994 FY | -1.05 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Medical Technologies Inc. | -926.89 Thousand USD | 100.0% |
| Ansell Limited | 76.5 Million USD | 100.0% |
| Ansell Limited | 76.5 Million USD | 100.0% |
| BG Medicine, Inc. | - USD | NaN% |
| Biotage AB (publ) | 24.28 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | -1.63 Million USD | 100.0% |
| Psykey, Inc. | -1.32 Million USD | 100.0% |
| ConvaTec Group Plc | 130.3 Million USD | 100.0% |
| ConvaTec Group Plc | 130.3 Million USD | 100.0% |
| Encision Inc. | -691.78 Thousand USD | 100.0% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 100.0% |
| Hear AtLast Holdings, Inc. | -234.36 Thousand USD | 100.0% |
| Innovative MedTech Inc. | -7.93 Million USD | 100.0% |
| LifePoint, Inc. | -15.23 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | -6.81 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | -474 Thousand USD | 100.0% |
| Remedent, Inc. | -274.44 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | -459.02 Thousand USD | 100.0% |
| SmileDirectClub, Inc. | -86.4 Million USD | 100.0% |
| Sector 10, Inc. | 7036.00 USD | 100.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 2 Billion USD | 100.0% |
| SheerVision, Inc. | -71.37 Thousand USD | 100.0% |
| United Health Products, Inc. | -2.62 Million USD | 100.0% |
| Vasamed, Inc. | -4.88 Million USD | 100.0% |
| Wearable Health Solutions, Inc. | -2.38 Million USD | 100.0% |
| Yubo International Biotech Limited | -1.2 Million USD | 100.0% |